Search Results 1031-1040 of 13928 for Assay

1. INCB161734 For Advanced Or Metastatic Solid Tumors With KRAS G12D Mutation - Mayo Clinic

   ... assay having a relevant mark of conformity for analytical performance (eg, CLIA [US] or UKCA, CE, CE UKNI, or others) to be eligible. Disease progression on ...

2. A Study Of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) In Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel In Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

   Known PD-L1 tumor status as determined by an IHC assay performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a ...

3. A Study To Assess Safety And Effectiveness Of Venetoclax In Combination With Gilteritinib In Subjects With Relapsed/Refractory Acute Myeloid Leukemia - Mayo Clinic

   ... assay using the established threshold of the chosen assay (i.e., PCR, NGS, etc.). No use or disclosure outside AbbVie is permitted without prior written ...

4. A Study To Evaluate The Efficacy And Safety Of Rozanolixizumab In Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) - Mayo Clinic

   Positivity for serum MOG-Immunglobulin G (IgG) antibodies using cell-based assay at Screening. Participant has history of relapsing MOG-AD with at least 1 ...

5. Study To Test The Safety And Tolerability Of PF-07257876 In Participants With Selected Advanced Tumors - Mayo Clinic

   PD-L1 IHC positivity ≥1% (regardless of CoDx™ assays). At least 1 measurable lesion, as defined by RECIST version 1.1, which has not been irradiated ...

6. Precision medicine for breast cancer - Mayo Clinic

   Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay.

7. REgulatory T Cell Therapy To Achieve Immunosuppression REduction - Mayo Clinic

   Note: Donor informed consent is required for donors participating in the research assay collection (anti-donor ELISPOT). Exclusion Criteria Based on SOC Pre ...

8. Publications - Hee Eun Lee, M.D., Ph.D. - Mayo Clinic

   ... Assay and Histopathologic Examination in Sentinel Lymph Nodes for Patients With Gastric Carcinoma. Am J Clin Pathol. 2016 May; 145 (5):651-9. View PubMed ...

9. A Study Of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) In Participants With Chronic Lymphocytic Leukemia (CLL) And Other B-cell Malignancies - Mayo Clinic

   ... assay 3. Must be actively taking zanubrutinib for at least 12 months. 4. Acceptable organ function at Screening within 28 days prior to Cycle 1 Day 1 (C1D1)

10. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM) - Mayo Clinic

    Serum free light-chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65). 5. Newly diagnosed and ...